iProgen Biotech
iProgen is a Vancouver-based biotech company pioneering next-generation antibody drug conjugate (ADC) discovery. They utilize innovative in-house developed Smart AntibodiesTM delivery technologies and next-generation smart Payloads such as oligonucleotides, PROTAC, and peptides. Their mission is to unlock the therapeutic potential of ADCs through expansive global collaborations with leaders in therapeutic research.
Industries
Nr. of Employees
small (1-50)
iProgen Biotech
8531 Commerce Crt., Burnaby, BC, Canada V5A4N4
Patents
Products
Antibody-based delivery platform
An internal antibody-based delivery platform designed to enable targeted delivery of diverse therapeutic payloads (including oligonucleotides, PROTACs, and peptides).
Antibody-based delivery platform
An internal antibody-based delivery platform designed to enable targeted delivery of diverse therapeutic payloads (including oligonucleotides, PROTACs, and peptides).
Services
Engineering and discovery support for design, conjugation, and optimization of antibody-drug conjugates to advance preclinical programs.
Co-development projects with academic institutions and industry partners, including participation in grant-supported research to develop novel antibody-payload modalities.
Services for cell line development, recombinant protein production, and characterization under cGMP-relevant workflows to support clinical manufacturing readiness.
Development and execution of analytical and functional assays to characterize antibodies and conjugates for lead selection and preclinical evaluation.
Engineering and discovery support for design, conjugation, and optimization of antibody-drug conjugates to advance preclinical programs.
Co-development projects with academic institutions and industry partners, including participation in grant-supported research to develop novel antibody-payload modalities.
Services for cell line development, recombinant protein production, and characterization under cGMP-relevant workflows to support clinical manufacturing readiness.
Development and execution of analytical and functional assays to characterize antibodies and conjugates for lead selection and preclinical evaluation.
Expertise Areas
- Antibody-drug conjugate (ADC) discovery and development
- Antibody engineering and optimization
- Protein engineering and delivery technologies
- Payload conjugation: oligonucleotides, PROTACs, peptides
Key Technologies
- Antibody-drug conjugation
- Antibody-based delivery platforms
- Oligonucleotide payload conjugation
- PROTAC payload integration
News & Updates
RIKEN Research Institute, KEIO Medical University, iPrime Therapeutics Co. Ltd., and iProgen Biotech enter joint research collaboration to discover novel lung cancer biomarkers.
Korean Basic Science Institute (KBSI) and iProgen Biotech Inc. enter research collaboration to explore the application of ADC technology to treat Osteoporosis.
Asan Medical Center (AMC) and iProgen Biotech Inc. enter research collaboration to explore the application of ADC technology to treat sarcopenia.
iProgen and UBC launch a two-year research collaboration supported by the National Science and Engineering Research Council to develop novel antibody-PROTAC technology.
Biorchestra and iProgen have been approved for an International Research Grant (Canada-Korea) to develop antibody oligo conjugates for various diseases.
RIKEN Research Institute, KEIO Medical University, iPrime Therapeutics Co. Ltd., and iProgen Biotech enter joint research collaboration to discover novel lung cancer biomarkers.
Korean Basic Science Institute (KBSI) and iProgen Biotech Inc. enter research collaboration to explore the application of ADC technology to treat Osteoporosis.
Asan Medical Center (AMC) and iProgen Biotech Inc. enter research collaboration to explore the application of ADC technology to treat sarcopenia.
iProgen and UBC launch a two-year research collaboration supported by the National Science and Engineering Research Council to develop novel antibody-PROTAC technology.
Biorchestra and iProgen have been approved for an International Research Grant (Canada-Korea) to develop antibody oligo conjugates for various diseases.